Ginkgo Bioworks Holdings (DNA) AI Stock Analysis

• Market Cap: $691.45M
• Dividend Yield: N/A
• Average Volume (3M): 1.70M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.78
• Revenue Growth: 25.21%
• EPS Growth: 67.53%
• Country: US
• Employees: 834
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -1.10
• Shares Outstanding: 47,089,600
• 10 Day Avg. Volume: 1,680,827
• 30 Day Avg. Volume: 1,697,229
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 2.43
• Enterprise Value/Gross Profit: 2.96
• Enterprise Value/Ebitda: -1.80
• 1Y Price Target: $12.50
• Price Target Upside: 7.02% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 3

• Rating: 55 Neutral
• Price Target: $14.00 ▲(19.86% Upside)

The overall stock score of 55 reflects a mixed outlook for Ginkgo Bioworks Holdings. The most significant factor is the company's financial performance, which shows strong gross margins but struggles with profitability and cash flow. The technical analysis indicates a positive trend, while the earnings call highlights cost reductions and strategic growth initiatives. However, the negative valuation metrics and potential risks in biosecurity revenue and leasing challenges temper the overall score.

Positive Factors

Cell Engineering Performance

Cell Engineering revenues drove the Q2 performance with 'High Value' programs up 10% year-over-year.

Cost Reduction

Ginkgo achieved its big cost-reduction target ahead of expectations, significantly reducing spending and making progress towards its goal of achieving positive EBITDA.

Revenue Growth

Ginkgo delivered 120 active revenue-generating cell programs in Q2, which is an increase of 10% year over year.

Negative Factors

Biosecurity Revenue Outlook

The company lowered its biosecurity revenue outlook for the year, citing greater uncertainty with its OUS business.

CFO Resignation

CFO Mark Dmytruk is resigning from his role to pursue a new role at a different company.

Hesitancy in Life Sciences

There is hesitancy in life science tools, particularly as it relates to outsourcing, which could impact future growth.

Ginkgo Bioworks Holdings Business Overview & Revenue Model

Company Description

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Ginkgo Bioworks primarily generates revenue through a combination of collaboration fees, milestone payments, and royalties from partnerships with companies across diverse industries. The company engages with partners to develop custom organisms that meet specific commercial needs, often entering into multi-year agreements that provide upfront payments and potential downstream revenue through royalties on sales of products developed using Ginkgo's engineered organisms. Additionally, Ginkgo Bioworks offers its expertise in cell programming as a service, providing access to its extensive biological engineering capabilities. Strategic collaborations and joint ventures further enhance its revenue streams, allowing the company to expand its reach and capitalize on its synthetic biology platform.

Ginkgo Bioworks Holdings Financial Statement Overview

Summary

Ginkgo Bioworks Holdings shows strong gross margins but struggles with profitability and cash flow, reflecting operational inefficiencies and growth challenges. The balance sheet is relatively stable, but the company needs to address its negative cash flows and improve its return on equity to enhance financial health.

Income Statement

The company exhibits a strong gross profit margin of over 82% in TTM, indicating effective cost management. However, the net profit margin is significantly negative, reflecting substantial losses. Revenue has declined over the past year, suggesting challenges in growth. The negative EBIT and EBITDA margins further highlight operational inefficiencies.

Balance Sheet

The debt-to-equity ratio is moderate, indicating a balanced approach to leveraging. However, the return on equity is negative, reflecting ongoing losses and inefficiencies in generating shareholder value. The equity ratio remains stable, suggesting a solid asset base relative to equity.

Cash Flow

The company faces negative operating and free cash flows, indicating cash burn. The free cash flow to net income ratio is above 1, suggesting that cash flow losses are less severe than accounting losses. However, the negative growth in free cash flow highlights ongoing cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	230.81M	227.04M	251.46M	477.71M	313.84M	76.66M
Gross Profit	189.72M	188.49M	197.45M	273.49M	184.15M	61.05M
EBITDA	-312.44M	-484.39M	-821.29M	-2.06B	-1.81B	-108.58M
Net Income	-315.19M	-547.03M	-892.87M	-2.10B	-1.83B	-126.61M
Balance Sheet
Total Assets	1.23B	1.38B	1.67B	2.54B	2.07B	675.15M
Cash, Cash Equivalents and Short-Term Investments	473.69M	561.57M	944.07M	1.32B	1.55B	380.80M
Total Debt	428.83M	467.73M	241.77M	442.59M	23.03M	17.00M
Total Liabilities	618.06M	661.39M	568.19M	803.04M	503.61M	205.10M
Stockholders Equity	612.95M	716.06M	1.10B	1.74B	1.51B	461.38M
Cash Flow
Free Cash Flow	-274.17M	-382.13M	-336.30M	-304.47M	-310.34M	-193.65M
Operating Cash Flow	-237.71M	-319.58M	-295.50M	-252.20M	-253.82M	-135.83M
Investing Cash Flow	-285.86M	-62.24M	-80.69M	-67.39M	-73.26M	-67.12M
Financing Cash Flow	-973.00K	-1.74M	-3.22M	95.34M	1.53B	90.32M

Ginkgo Bioworks Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.68
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNA, the sentiment is Neutral. The current price of 11.68 is below the 20-day moving average (MA) of 12.20, below the 50-day MA of 12.04, and above the 200-day MA of 9.72, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 44.30 is Neutral, neither overbought nor oversold. The STOCH value of 25.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DNA.

Ginkgo Bioworks Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MAZE	59 Neutral	$671.80M	―		―	―	―
DNA	55 Neutral	$691.45M	―	-43.59%	―	25.21%	67.53%
Sector *	51 Neutral	$7.92B	-0.43	-41.69%	2.21%	22.29%	-1.85%
TRML	45 Neutral	$644.88M	―	-29.62%	―	―	6.66%
RAPP	44 Neutral	$560.24M	―	-29.42%	―	―	―
ERAS	34 Underperform	$419.83M	―	-31.16%	―	―	50.77%
SANA	33 Underperform	$770.93M	―	-109.12%	―	―	7.58%

Ginkgo Bioworks Holdings Corporate Events

Ginkgo Bioworks Enters Sales Agreement for Stock Offering

On September 4, 2025, Ginkgo Bioworks Holdings entered into a Sales Agreement with Allen & Company LLC to potentially sell up to $100 million of its Class A common stock in at-the-market offerings. The proceeds from these sales, if any, are intended for general corporate purposes, including financing operations and technology development. The agreement allows flexibility in selling shares and includes customary rights and termination options for both parties. This move could impact the company’s market positioning by providing additional capital to support its growth and operations in the competitive synthetic biology industry.

Ginkgo Bioworks Settles Stockholder Derivative Actions

On May 27, 2025, Ginkgo Bioworks Holdings reached a Stipulation and Agreement of Settlement to resolve stockholder derivative actions against certain individuals. The settlement, preliminarily approved by the court on August 21, 2025, includes a $4,125,000 insurance-funded payment, corporate governance reforms, and the dismissal of the actions. A final hearing is set for December 18, 2025.

Ginkgo Bioworks Holds Annual Shareholder Meeting, Elects Directors

On June 12, 2025, Ginkgo Bioworks Holdings, Inc. conducted its annual meeting of shareholders, where a significant majority of shares were represented. The meeting resulted in the election of seven directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, shareholders approved the executive compensation on an advisory basis, indicating broad support for the company’s leadership and strategic direction.